Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Name: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Published: 2016
License: Public Domain

Janssen Research & Development, LLC · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

non-small-cell-lung-cancer

non-small-cell lung cancer, amivantamab, first-in-human, human bispecific epidermal growth factor receptor (egfr), c-mesenchymal-epithelial transition (cmet) antibody, jnj372, exon 20, exon 20 insertion, tyrosine kinase inhibitor (tki) resistant, tki resistance, egfr c797s, met amplification

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 852284
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.